Moderna publishes presentation on Phase 3 intismeran melanoma study
MRNA•Moderna published a presentation featuring Phase 3 INTerpath-001 results for intismeran autogene, reporting a recurrence-free survival benefit maintained through five years of follow-up.
1. Study results
The trial compares intismeran autogene plus pembrolizumab with pembrolizumab alone as adjuvant treatment for resected stage IIB-IV melanoma. Moderna’s presentation reports that the recurrence-free survival benefit was maintained through five years of follow-up.
